ClinicalTrials.gg
CompletedNCT02876835Updated Apr 2, 2024Results posted

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

A Phase 3 interventional study of Daprodustat and Darbepoetin alfa in Anaemia, sponsored by GlaxoSmithKline. Completed at 578 sites in 39 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-04-02.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,872
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.

Enrollment
Largest of 30
3,872 · median 76
Started
2016
with 4 others
Phase 3
9 of 30
1 open now
Registered
16th of 30
by date
Lead sponsor
28 of 30
GlaxoSmithKline

Among the 30 studies testing GSK1278863 in Anemia, this one has the largest enrollment, is one of 5 that started in 2016, is one of 9 in phase 3, and was the 16th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:

About GSK1278863

GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing GSK1278863 in Anemia, or all of them as a file.
02

Study summary

The purpose of this multi-center event-driven study in non-dialysis (ND) participants with anemia associated with chronic kidney disease (CKD) is to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.

03

Conditions studied

  • Anaemia

Keywords

  • GSK1278863
  • hemoglobin
  • anemia
  • non-dialysis
  • erythropoiesis stimulating agents
  • daprodustat
  • chronic kidney disease
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18 to 99 years of age (inclusive)
  • CKD stage: Kidney Disease Outcomes Quality Initiative (KDOQI) CKD stages 3, 4, or 5 defined by electronic using the CKD Epidemiology Collaboration (CKD-EPI) formula.
  • Erythropoietin-stimulating agents (ESAs)/: Group 1 (not using ESAs): No ESA use within the 6 weeks prior to screening and no ESA use between screening and randomization (Day 1). Group 2 (ESA users): Use of any approved ESA for the 6 weeks prior to screening and continuing between screening and randomization.
  • For Group 1 (not using ESAs), Hgb concentration at Week -8 and Week 1 should be 8 to 10 gram per deciliter (g/dL). For Group 2 (ESA users), Hgb concentration at Week -8 should be 8 to 12 g/dL and at Week 1 should be 8 to 11 g/dL.
  • >=80% and \<=120% compliance with placebo during run-in period.
  • (screening only): capable of giving signed informed consent which includes compliance with the requirements and restrictions.

Exclusion criteria

Exclusion Criteria:

  • Dialysis: On dialysis or clinical evidence of impending need to initiate dialysis within 90 days after study start (Day 1).
  • Kidney transplant: Planned living-related or living-unrelated kidney transplant within 52 weeks after study start (Day 1).
  • Ferritin: \<=100 nanograms (ng)/milliliter (mL) (\<=100 micrograms/liter [L]) at screening.
  • Transferrin saturation (TSAT) (screening only): \<=20%.
  • Aplasias: History of bone marrow aplasia or pure red cell aplasia.
  • Other causes of anemia: untreated pernicious anemia, thalassemia major, sickle cell disease or myelodysplastic syndrome.
  • Gastrointestinal (GI) bleeding: Evidence of actively bleeding gastric, duodenal, or esophageal ulcer disease or GI bleeding \<=4 weeks prior to screening through to randomization (Day 1).
  • MI or acute coronary syndrome: \<=4 weeks prior to screening through to randomization (Day 1).
  • Stroke or : \<=4 weeks prior to screening through to randomization (Day 1).
  • Heart failure (HF): Chronic Class IV HF, as defined by the (NYHA) functional classification system.
  • Current uncontrolled hypertension: Current uncontrolled hypertension as determined by the investigator.
  • Bazett's interval (QTcB) (Day 1): QTcB >500 millisecond (msec), or QTcB >530 msec in subjects with bundle branch block. There is no Q-T Interval Corrected for Heart Rate (QTc) exclusion for subjects with a predominantly ventricular paced rhythm.
  • (ALT): >2x (ULN) at screening.
  • : >1.5xULN at screening.
  • Current unstable liver or biliary disease per investigator assessment, generally defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.
  • : History of malignancy within the 2 years prior to screening through to randomization (Day 1) or currently receiving treatment for cancer, or complex kidney cyst (example [e.g.] Bosniak Category II F, III or IV) > 3 centimeter (cm); with the exception of localized squamous cell or basal cell carcinoma of the skin that has been definitively treated >=4 weeks prior to screening.
  • Severe allergic reactions: History of severe allergic or anaphylactic reactions or to in the product, or darbepoetin alfa.
  • Drugs and supplements: Use of strong inhibitors of Cytochrome P4502C8 (CYP2C8) (e.g., gemfibrozil) or strong inducers of CYP2C8 (e.g., rifampin/rifampicin).
  • Other study participation: Use of other investigational agent or device prior to screening through to randomization (Day 1). At screening, this exclusion applies to use of the investigational agent within 30 days or within five half lives (whichever is longer).
  • Prior treatment with daprodustat: Any prior treatment with daprodustat for treatment duration of >30 days.
  • Females only: Subject is pregnant [as confirmed by a positive urine human chorionic gonadotrophin (hCG) test for females of (FRP) only], subject is breastfeeding, or subject is of reproductive potential and does not agree to follow one of the options.
  • Other Conditions: Any other condition, clinical or laboratory abnormality, or examination finding that the investigator considers would put the subject at unacceptable risk, which may affect study compliance (e.g., intolerance to darbepoetin alfa) or prevent understanding of the aims or investigational procedures or possible consequences of the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,872 participants (actual)

Study arms

  • Experimental
    Daprodustat

    Participants will receive oral daprodustat once daily.

    Drug: Daprodustat · Drug: Placebo · Drug: Iron Therapy

  • Active comparator
    Darbepoetin alfa

    Participants will be administered darbepoetin alfa subcutaneously (SC).

    Drug: Darbepoetin alfa · Drug: Placebo · Drug: Iron Therapy

Interventions

  • The initial dose or oral daprodustat for ESA naïve subjects is based on Hgb and for ESA users is based on prior ESA dose. The dose is adjusted thereafter in order to achieve the target range.

  • The initial dose of darbepoetin alfa to be administered for SC injection for ESA naïve subjects is based in Hgb and weight, and for ESA users is based on converting the prior ESA dose to the nearest available study darbepoetin alfa dose. The dose is adjusted thereafter in order to achieve the target range. IV darbepoetin alfa can be considered for participants transitioning to hemodialysis.

  • DrugPlacebo

    Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).

  • DrugIron Therapy

    Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.

06

What researchers measure

Primary outcomes

  1. Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period (Non-inferiority Analysis)

    Time to MACE defined as time to first occurrence of Clinical Events Committee (CEC) adjudicated MACE (composite of all-cause mortality, non-fatal myocardial infarction \[MI\] and non-fatal stroke) was analyzed using a Cox proportional hazards regression model with treatment group, current erythropoiesis-stimulating agents (ESA) use at randomization and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) plus (+) 1. The incidence rate per 100 person years calculated as (100 multiplied \[\*\] number of participants with at least 1 event) divided by \[/\] first event person-years) is presented along with 95 percent (%) confidence interval (CI). First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 4.3 person-years for CV follow-up time period

  2. Mean Change From Baseline in Hgb Levels Over the Evaluation Period (Week 28 to Week 52)

    Blood samples were collected from participants for Hgb measurements. Hgb during the evaluation period was defined as the mean of all available post-randomization Hgb values (on and off-treatment) during the evaluation period (Week 28 to Week 52). For the primary analysis missing post-Baseline Hgb values were imputed using pre-specified multiple imputation methods. Change from Baseline was defined as post-Baseline value minus (-) Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using the Analysis of covariance (ANCOVA) model with terms for treatment, Baseline Hgb, current ESA use and region.

    Time frame: Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52)

Secondary outcomes

  1. Time to First Occurrence of Adjudicated MACE During CV Events Follow-up Time Period (Superiority Analysis)

    Time to MACE defined as the time to first occurrence of CEC adjudicated MACE was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariate. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period. This endpoint was adjusted for multiplicity using the Holm-Bonferonni method.

    Time frame: Up to 4.3 person-years for CV follow-up time period

  2. Time to First Occurrence of Adjudicated MACE or Thromboembolic Event During CV Events Follow-up Time Period

    Time to first occurrence of adjudicated MACE or thromboembolic event (vascular access thrombosis, symptomatic deep vein thrombosis or symptomatic pulmonary embolism) was analyzed using a Cox proportional hazards regression model with with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period. This endpoint was adjusted for multiplicity using the Holm-Bonferonni method.

    Time frame: Up to 4.3 person-years for CV follow-up time period

  3. Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure During CV Events Follow-up Time Period

    Time to first occurrence of adjudicated MACE or hospitalization for heart failure was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period. This endpoint was adjusted for multiplicity using the Holm-Bonferonni method.

    Time frame: Up to 4.3 person-years for CV follow-up time period

  4. Time to First Occurrence of Chronic Kidney Disease (CKD) Progression During CV Events Follow-up Time Period

    Progression of CKD defined as: 40% decline in estimated glomerular filtration rate (eGFR) from Baseline or end stage renal disease (ESRD) as defined by either initiating chronic dialysis for \>=90 days or not initiating chronic dialysis when dialysis is indicated or kidney transplantation. Time to first occurrence of CKD progression was analyzed using Fine and Gray's proportional subdistribution hazard regression model with treatment group, Baseline ESA use and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) +1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event+cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 4.3 person-years for CV follow-up time period

  5. Time to First Occurrence of Adjudicated All-Cause Mortality During Vital Status for Follow-up Time Period

    Time to first occurrence of adjudicated all-cause mortality was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the vital status follow-up time period.

    Time frame: Up to 4.3 person-years for vital status follow-up time period

  6. Time to First Occurrence of Adjudicated CV Mortality During CV Events Follow-up Time Period

    Time to first occurrence of adjudicated CV mortality was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 4.3 person-years for CV follow-up time period

  7. Time to First Occurrence of Adjudicated Myocardial Infarction (MI) (Fatal and Non-Fatal) During CV Events Follow-up Time Period

    Time to first occurrence of adjudicated MI (fatal and non-fatal) was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 4.3 person-years for CV follow-up time period

  8. Time to First Occurrence of Adjudicated Stroke (Fatal and Non-Fatal) During CV Events Follow-up Time Period

    Time to first occurrence of adjudicated stroke (fatal and non-fatal) was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 4.3 person-years for CV follow-up time period

  9. Number of Participants With Adjudicated MACE or Hospitalization for Heart Failure (Recurrent Events Analysis)

    Number of participants with adjudicated MACE or hospitalization for heart failure (recurrent events analysis) is presented, categorized by number of occurrences of adjudicated MACE or hospitalization for heart failure per participant.

    Time frame: Up to 4.3 person-years for CV follow-up time period

  10. Time to First Occurrence of Adjudicated CV Mortality or Non-Fatal MI During CV Events Follow-up Time Period

    Time to first occurrence of adjudicated CV mortality or non-fatal MI was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 4.3 person-years for CV follow-up time period

  11. Time to First Occurrence of All-Cause Hospitalization During CV Events Follow-up Time Period

    All-cause hospitalization events were hospital admissions recorded on the hospitalization electronic case report form (eCRF) form with a hospitalization duration \>=24 hours. Time to first occurrence of all-cause hospitalization was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 4.3 person-years for CV follow-up time period

  12. Time to First Occurrence of All-Cause Hospital Re-admission Within 30 Days During CV Events Follow-up Time Period

    All-cause hospital re-admissions within 30days are defined as hospital admissions recorded on hospitalization electronic case record form with hospitalization duration of \>=24 hours and admission date within 30days following previous discharge date of all-cause hospitalization event, where previous hospitalization was \>=24hours.Time to first occurrence of all-cause hospital re-admission within 30days was analyzed using Cox proportional hazards regression model with treatment group, current ESA use at randomization and region as covariates.Time to the first occurrence was computed as(event date - randomization date)+1. Incidence rate per 100 person years calculated as(100\*number of participants with at least 1event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event+cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 4.3 person-years for CV follow-up time period

  13. Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure or Thromboembolic Events During CV Events Follow-up Time Period

    Time to first occurrence of adjudicated MACE or hospitalization for heart failure or thromboembolic events were analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 4.3 person-years for CV follow-up time period

  14. Time to First Occurrence of Adjudicated Hospitalization for Heart Failure During CV Events Follow-up Time Period

    Time to first occurrence of adjudicated hospitalization for heart failure was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 4.3 person-years for CV follow-up time period

  15. Time to First Occurrence of Adjudicated Thromboembolic Events During CV Events Follow-up Time Period

    Time to first occurrence of adjudicated thromboembolic events were analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 4.3 person-years for CV follow-up time period

  16. Time to First Occurrence of Confirmed 40% Decline in eGFR During CV Events Follow-up Time Period

    Time to first occurrence of confirmed 40% decline in eGFR was analyzed using a Fine \& Gray's proportional subdistribution hazard regression model with treatment group, Baseline ESA use and region as covariates. Time to the first occurrence was computed as (event date minus randomization date)+1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 4.3 person-years for CV follow-up time period

  17. Time to First Occurrence of Chronic Dialysis During CV Events Follow-up Time Period

    Time to first occurrence of chronic dialysis was analyzed using a Fine \& Gray's proportional subdistribution hazard regression model with treatment group, Baseline ESA use and region as covariates. Chronic dialysis is defined by either initiating dialysis for \>=90 days or not initiating chronic dialysis when dialysis is indicated. Time to the first occurrence was computed as (event date minus randomization date)+1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 4.3 person-years for CV follow-up time period

  18. Time to First Occurrence of Kidney Transplant During CV Events Follow-up Time Period

    Time to first occurrence of kidney transplant were analyzed using a Fine \& Gray's proportional subdistribution hazard regression model with treatment group, Baseline ESA use and region as covariates. Time to the first occurrence was computed as (event date minus randomization date)+1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

    Time frame: Up to 4.3 person-years for CV follow-up time period

  19. Change From Baseline in Post-randomization Hgb Levels at Week 52

    Blood samples were collected from participants for Hgb measurements. Change from Baseline was defined as post-randomization value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using mixed model repeated measures (MMRM) model fitted from Baseline up to Week 52, excluding values collected during the stabilization period, with factors for treatment, time, current ESA use, region, Baseline Hgb and Baseline Hgb by time and treatment by time interactions.

    Time frame: Baseline (Pre-dose on Day 1) and Week 52

  20. Number of Hgb Responders in the Hgb Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)

    Mean Hgb during the evaluation period was defined as the mean of all evaluable Hgb values during the evaluation period (Week 28 to Week 52) including any evaluable unscheduled Hgb values that were taken during this time period. Hgb responders were defined as participants with a mean Hgb during the evaluation period that falls within the Hgb analysis range of 10-11.5 g/dL.

    Time frame: Week 28 to Week 52

  21. Percentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Non-inferiority Analysis

    Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the evaluation period (Week 28 to Week 52), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during evaluation period is calculated as time in range during the evaluation period / \[Earlier of (Date of the last evaluable Hgb value, Week 52 visit date) - Later of (Date of the first evaluable Hgb value that between Week 16 and Week 52 inclusive, Week 28 visit date)\].

    Time frame: Week 28 to Week 52

  22. Percentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Superiority Analysis

    Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the evaluation period (Week 28 to Week 52), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during evaluation period is calculated as time in range during the evaluation period / \[Earlier of (Date of the last evaluable Hgb value, Week 52 visit date) - Later of (Date of the first evaluable Hgb value that between Week 16 and Week 52 inclusive, Week 28 visit date)\].

    Time frame: Week 28 to Week 52

  23. Percentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Non-inferiority Analysis

    Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the maintenance period (Week 28 to end of study), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during maintenance period is calculated as time in range during the maintenance period / \[Earlier of (Date of the last evaluable Hgb value, End of study date)- Later of (Date of the first evaluable Hgb value that is on or after week 16, Week 28 visit date)\].

    Time frame: Week 28 to end of study (4.3 person-years for follow-up time period)

  24. Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Superiority Analysis

    Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the maintenance period (Week 28 to end of study), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during maintenance period is calculated as time in range during the maintenance period / \[Earlier of (Date of the last evaluable Hgb value, End of study date)- Later of (Date of the first evaluable Hgb value that is on or after week 16, Week 28 visit date)\].

    Time frame: Week 28 to end of study (4.3 person-years for follow-up time period)

  25. Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Blood Pressure (MAP) at Week 52

    SBP, DBP and MAP were measured in a seated position after at least a 5-minutes of rest. MAP is the average (BP) in an individual's arteries during a single cardiac cycle. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using MMRM model with treatment group + time + current ESA use at randomization + region + Baseline value + Baseline value\*time + treatment group\*time, using an unstructured covariance matrix. Data for post-dialysis BP measurements have been presented.

    Time frame: Baseline (Week -4) and Week 52

  26. Change From Baseline in SBP, DBP, MAP at End of Treatment

    SBP, DBP and MAP were measured in a seated position after at least a 5-minutes of rest. MAP is an average BP in an individual's arteries during a single cardiac cycle. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using ANCOVA model with terms for treatment group, current ESA use at randomization, region and Baseline value. Data for post-dialysis BP measurements have been presented.

    Time frame: Baseline (Week -4) and 51.1 months

  27. Blood Pressure (BP) Exacerbation Event Rate Per 100 Participant Years

    BP exacerbation event (based on post-dialysis) was defined as: SBP \>= 25 millimeter of mercury (mmHg) increased from Baseline or SBP \>=180 mmHg; DBP \>=15 mmHg increased from Baseline or DBP \>=110 mmHg. The BP exacerbation events per 100 participant years was estimated using the negative binomial model with treatment, current ESA use at randomization and region as covariates and the logarithm of time on-treatment as an offset variable. Data for post-dialysis BP measurements have been presented.

    Time frame: Day 1 to end of treatment (51.1 months)

  28. Number of Participants With at Least One BP Exacerbation Event During Study

    BP exacerbation was defined as: SBP \>= 25 mmHg increased from Baseline or SBP \>=180 mmHg; DBP \>=15 mmHg increased from Baseline or DBP \>=110 mmHg. Number of participants with at least one BP exacerbation event is presented.

    Time frame: Day 1 to end of treatment (51.1 months)

  29. Percentage of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria

    Percentage of participants permanently stopping randomized treatment due to meeting rescue criteria has been presented.

    Time frame: Day 1 to 51.1 months

  30. Change From Baseline in On-treatment Physical Component Score (PCS) Using Short Form (SF)-36 Health-related Quality of Life (HRQoL) Questionnaire at Weeks 8, 12, 28, 52

    The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). The PCS is an average score derived from 4 domains (physical functioning, role-physical, bodily pain and general health) representing overall physical health. PCS ranges from 0 to 100; higher score represents better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52

  31. Change From Baseline in On-treatment Mental Component Score (MCS) Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52

    The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). MCS is an average score derived from 4 domains (vitality, social functioning, role-emotional and mental health) representing overall mental health. MCS ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52

  32. Change From Baseline in On-treatment SF-36 HRQoL Scores for Bodily Pain, General Health, Mental Health, Role-Emotional, Role-Physical, Social Functioning at Weeks 8, 12, 28, 52

    The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: bodily pain (b pain), general health (GH), mental health (MH), role-emotional (RE) (role limitations caused by emotional problems), role-physical (RP) (role limitations caused by physical problems), social functioning (SF), physical functioning and vitality. Each domain is scored from 0 (poorer health) to 100 (better health). Each domain score ranges from 0 to 100, higher score indicates a better health state and better functioning. Change from Baseline (BL) was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52

  33. Change From Baseline in On-treatment Vitality Scores Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52

    The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). Vitality score ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52

  34. Change From Baseline in On-treatment Physical Functioning Domain Scores Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52

    The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). Physical functioning score ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52

  35. Change From Baseline in On-treatment Health Utility EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire Score at Week 52

    EQ-5D-5L is self-assessment questionnaire, consisting of 5 items covering 5 dimensions (mobility, self care, usual activities, pain/discomfort and anxiety/depression). Each dimension is measured by 5-point Likert scale (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Each of these 5 figure health states were converted to a single index score by applying country-specific value set formula that attaches weights to dimensions and levels. Range for EQ-5D-5L index score is -0.594 (worst health) to 1 (full health state). Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was latest non-missing pre-dose assessment on or before randomization date.

    Time frame: Baseline (Pre-dose on Day 1) and Week 52

  36. Change From Baseline in On-treatment EQ Visual Analogue Scale (EQ-VAS) at Week 52

    The EQ VAS records the respondent's self-rated health on a vertical VAS, ranging from 0 to 100, where 0 represents the worst imaginable health and 100 represents the best imaginable health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Pre-dose on Day 1) and Week 52

  37. Change From Baseline in On-treatment Chronic Kidney Disease- Anemia Symptoms Questionnaire (CKD-AQ) at Weeks 8, 12, 28, 52

    CKD-AQ is 21-item patient reported outcome measure assessing symptoms and symptom impact in participants with anemia associated with CKD. It had 3 domains: 1.Tired/Low Energy (LE)/Weak scale consisting of 10 items; 2.Chest Pain (CP)/Shortness of Breath (SOB) scale consisting of 4 items; and 3.Cognitive (Cog) scale consisting of 3 items. The 4 CKD-AQ single items are: shortness of breath, no activity; severity-short breath (S-SB), resting; difficulty standing (diff. std.)for long time (LT) and difficulty sleeping (diff sleep). Single-item were recorded based on a 0-100 scoring with 0=worst possible and 100=best possible score. Three domains scores were calculated as average of items in each domain and ranged from 0-100 where 0=worst possible and 100=best possible score. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Day 1) and Weeks 8, 12, 28, 52

  38. Change From Baseline in On-treatment Patient Global Impression of Severity (PGI-S) at Weeks 8, 12, 28, 52

    The PGI-S is a 1-item questionnaire designed to assess participant's impression of disease severity on a 5-point disease severity scale (0=absent, 1=mild, 2=moderate, 3=severe, or 4=very severe). A higher score indicated more disease severity. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52

  39. Change From Baseline in Post-randomization Estimated Glomerular Filtration Rate (eGFR) at Week 52

    Blood samples were collected to analyze estimated glomerular filtration rate. Change from Baseline was calculated as post-Baseline visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

    Time frame: Baseline (Pre-dose on Day 1) and Week 52

07

Results

Posted Apr 14, 2022

Participant flow

This was a multicenter study conducted across 39 countries. Participants were randomized to receive either daprodustat or darbepoetin alfa.

Run-in Period: Placebo (Week-4 to Day 1)
Participant flow — Run-in Period: Placebo (Week-4 to Day 1)
MilestoneDaprodustatDarbepoetin Alfa
Started19371935
Completed19371935
Not completed00
Treatment Period (51.1 Month)
Participant flow — Treatment Period (51.1 Month)
MilestoneDaprodustatDarbepoetin Alfa
Started19371935
Completed18731870
Not completed6465
Withdrew: Other10
Withdrew: Investigator site closed613
Withdrew: Withdrawal by subject3223
Withdrew: Lost to follow-up2529

Outcome measures

PrimaryTime to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period (Non-inferiority Analysis)

Time to MACE defined as time to first occurrence of Clinical Events Committee (CEC) adjudicated MACE (composite of all-cause mortality, non-fatal myocardial infarction \[MI\] and non-fatal stroke) was analyzed using a Cox proportional hazards regression model with treatment group, current erythropoiesis-stimulating agents (ESA) use at randomization and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) plus (+) 1. The incidence rate per 100 person years calculated as (100 multiplied \[\*\] number of participants with at least 1 event) divided by \[/\] first event person-years) is presented along with 95 percent (%) confidence interval (CI). First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 4.3 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period (Non-inferiority Analysis)
Events per 100 person yearsDaprodustatDarbepoetin Alfa
Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period (Non-inferiority Analysis)10.86 (9.80 to 12.02)10.63 (9.58 to 11.77)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Hazard ratio (hr): 1.03 · 95% CI 0.89 to 1.19Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, current ESA use at randomization, and region as covariates.
PrimaryMean Change From Baseline in Hgb Levels Over the Evaluation Period (Week 28 to Week 52)

Blood samples were collected from participants for Hgb measurements. Hgb during the evaluation period was defined as the mean of all available post-randomization Hgb values (on and off-treatment) during the evaluation period (Week 28 to Week 52). For the primary analysis missing post-Baseline Hgb values were imputed using pre-specified multiple imputation methods. Change from Baseline was defined as post-Baseline value minus (-) Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using the Analysis of covariance (ANCOVA) model with terms for treatment, Baseline Hgb, current ESA use and region.

Time frame:
Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52)
Reported as:
Least squares mean · Grams per deciliter
Mean Change From Baseline in Hgb Levels Over the Evaluation Period (Week 28 to Week 52)
Grams per deciliterDaprodustatDarbepoetin Alfa
Mean Change From Baseline in Hgb Levels Over the Evaluation Period (Week 28 to Week 52)0.74 ± 0.0190.66 ± 0.019
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Least square (ls) mean difference: 0.08 · 95% CI 0.03 to 0.13
SecondaryTime to First Occurrence of Adjudicated MACE During CV Events Follow-up Time Period (Superiority Analysis)

Time to MACE defined as the time to first occurrence of CEC adjudicated MACE was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariate. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period. This endpoint was adjusted for multiplicity using the Holm-Bonferonni method.

Time frame:
Up to 4.3 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated MACE During CV Events Follow-up Time Period (Superiority Analysis)
Events per 100 person yearsDaprodustatDarbepoetin Alfa
Time to First Occurrence of Adjudicated MACE During CV Events Follow-up Time Period (Superiority Analysis)10.86 (9.80 to 12.02)10.63 (9.58 to 11.77)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Wald test · p = 0.670884 (The p-value was compared against 0.008333 based on the Holm-Bonferonni adjustment.) · Hazard ratio (hr): 1.03 · 95% CI 0.89 to 1.19Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, current ESA use at randomization, and region as covariates.
SecondaryTime to First Occurrence of Adjudicated MACE or Thromboembolic Event During CV Events Follow-up Time Period

Time to first occurrence of adjudicated MACE or thromboembolic event (vascular access thrombosis, symptomatic deep vein thrombosis or symptomatic pulmonary embolism) was analyzed using a Cox proportional hazards regression model with with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period. This endpoint was adjusted for multiplicity using the Holm-Bonferonni method.

Time frame:
Up to 4.3 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated MACE or Thromboembolic Event During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatDarbepoetin Alfa
Time to First Occurrence of Adjudicated MACE or Thromboembolic Event During CV Events Follow-up Time Period12.34 (11.19 to 13.57)11.77 (10.65 to 12.98)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Wald test · p = 0.800813 (The p-value was compared against 0.012500 based on the Holm-Bonferonni adjustment.) · Hazard ratio (hr): 1.06 · 95% CI 0.93 to 1.22Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, current ESA use at randomization, and region as covariates.
SecondaryTime to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure During CV Events Follow-up Time Period

Time to first occurrence of adjudicated MACE or hospitalization for heart failure was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period. This endpoint was adjusted for multiplicity using the Holm-Bonferonni method.

Time frame:
Up to 4.3 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatDarbepoetin Alfa
Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure During CV Events Follow-up Time Period13.16 (11.97 to 14.44)12.22 (11.08 to 13.46)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Wald test · p = 0.886195 (The p-value was compared against 0.025000 based on the Holm-Bonferonni adjustment.) · Hazard ratio (hr): 1.09 · 95% CI 0.95 to 1.24Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, current ESA use at randomization, and region as covariates.
SecondaryTime to First Occurrence of Chronic Kidney Disease (CKD) Progression During CV Events Follow-up Time Period

Progression of CKD defined as: 40% decline in estimated glomerular filtration rate (eGFR) from Baseline or end stage renal disease (ESRD) as defined by either initiating chronic dialysis for \>=90 days or not initiating chronic dialysis when dialysis is indicated or kidney transplantation. Time to first occurrence of CKD progression was analyzed using Fine and Gray's proportional subdistribution hazard regression model with treatment group, Baseline ESA use and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) +1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event+cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 4.3 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Chronic Kidney Disease (CKD) Progression During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatDarbepoetin Alfa
Time to First Occurrence of Chronic Kidney Disease (CKD) Progression During CV Events Follow-up Time Period17.55 (15.74 to 19.51)17.76 (15.97 to 19.70)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Wald test · p = 0.369470 · Subdistribution hazard ratio: 0.98 · 95% CI 0.84 to 1.13Subdistribution hazard ratio was estimated using Fine and Gray's proportional subdistribution hazard regression model with treatment group, Baseline ESA use, and region as covariates.
SecondaryTime to First Occurrence of Adjudicated All-Cause Mortality During Vital Status for Follow-up Time Period

Time to first occurrence of adjudicated all-cause mortality was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the vital status follow-up time period.

Time frame:
Up to 4.3 person-years for vital status follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated All-Cause Mortality During Vital Status for Follow-up Time Period
Events per 100 person yearsDaprodustatDarbepoetin Alfa
Time to First Occurrence of Adjudicated All-Cause Mortality During Vital Status for Follow-up Time Period8.35 (7.43 to 9.35)8.27 (7.35 to 9.26)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Wald test · p = 0.6197 · Hazard ratio (hr): 1.03 · 95% CI 0.87 to 1.20Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, current ESA use at randomization, and region as covariates.
SecondaryTime to First Occurrence of Adjudicated CV Mortality During CV Events Follow-up Time Period

Time to first occurrence of adjudicated CV mortality was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 4.3 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated CV Mortality During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatDarbepoetin Alfa
Time to First Occurrence of Adjudicated CV Mortality During CV Events Follow-up Time Period3.02 (2.48 to 3.65)2.55 (2.06 to 3.13)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Wald test · p = 0.8976 · Hazard ratio (hr): 1.20 · 95% CI 0.91 to 1.58Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, current ESA use at randomization, and region as covariates.
SecondaryTime to First Occurrence of Adjudicated Myocardial Infarction (MI) (Fatal and Non-Fatal) During CV Events Follow-up Time Period

Time to first occurrence of adjudicated MI (fatal and non-fatal) was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 4.3 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated Myocardial Infarction (MI) (Fatal and Non-Fatal) During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatDarbepoetin Alfa
Time to First Occurrence of Adjudicated Myocardial Infarction (MI) (Fatal and Non-Fatal) During CV Events Follow-up Time Period2.94 (2.40 to 3.56)2.76 (2.24 to 3.36)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Wald test · p = 0.6581 · Hazard ratio (hr): 1.06 · 95% CI 0.80 to 1.40Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, current ESA use at randomization, and region as covariates.
SecondaryTime to First Occurrence of Adjudicated Stroke (Fatal and Non-Fatal) During CV Events Follow-up Time Period

Time to first occurrence of adjudicated stroke (fatal and non-fatal) was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 4.3 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated Stroke (Fatal and Non-Fatal) During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatDarbepoetin Alfa
Time to First Occurrence of Adjudicated Stroke (Fatal and Non-Fatal) During CV Events Follow-up Time Period1.26 (0.92 to 1.69)0.95 (0.66 to 1.33)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Wald test · p = 0.8940 · Hazard ratio (hr): 1.33 · 95% CI 0.85 to 2.07Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, current ESA use at randomization, and region as covariates.
SecondaryNumber of Participants With Adjudicated MACE or Hospitalization for Heart Failure (Recurrent Events Analysis)

Number of participants with adjudicated MACE or hospitalization for heart failure (recurrent events analysis) is presented, categorized by number of occurrences of adjudicated MACE or hospitalization for heart failure per participant.

Time frame:
Up to 4.3 person-years for CV follow-up time period
Reported as:
Count of participants · Participants
Number of Participants With Adjudicated MACE or Hospitalization for Heart Failure (Recurrent Events Analysis)
ParticipantsDaprodustatDarbepoetin Alfa
Occurrences per participant: 014931518
Occurrences per participant: 1318317
Occurrences per participant: 27664
Occurrences per participant: 32622
Occurrences per participant: 4149
Occurrences per participant: 553
Occurrences per participant: 610
Occurrences per participant: 741
Occurrences per participant: 801
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Chi-squared · p = 0.9422 · Hazard ratio (hr): 1.10 · 95% CI 0.98 to 1.23Overall HR is presented using Model 1. Model 1 assumed a common treatment effect, regardless of number of events experienced. HR was estimated using a Prentice, Williams and Peterson(PWP) model, with treatment, dialysis type and region as covariates.
  • Daprodustat vs Darbepoetin Alfa · Chi-squared · p = 0.8862 · Hazard ratio (hr): 1.09 · 95% CI 0.95 to 1.24First Event Hazard ratio is presented using Model 2. Model 2 assumed treatment effect differs by number of events experienced. Hazard Ratio (HR) was estimated using a PWP model, with treatment, dialysis type and region as covariates.
  • Daprodustat vs Darbepoetin Alfa · Chi-squared · p = 0.6789 · Hazard ratio (hr): 1.07 · 95% CI 0.82 to 1.39Second Event Hazard ratio is presented using Model 2. Model 2 assumed treatment effect differs by number of events experienced. HR was estimated using a PWP model, with treatment, dialysis type and region as covariates.
  • Daprodustat vs Darbepoetin Alfa · Chi-squared · p = 0.9016 · Hazard ratio (hr): 1.37 · 95% CI 0.85 to 2.19Third Event Hazard ratio is presented using Model 2. Model 2 assumed treatment effect differs by number of events experienced. HR was estimated using a PWP model, with treatment, dialysis type and region as covariates.
  • Daprodustat vs Darbepoetin Alfa · Chi-squared · p = 0.8862 · Hazard ratio (hr): 1.09 · 95% CI 0.95 to 1.24First Event Hazard ratio is presented using Model 3. Model 3 assumed treatment effect for first event differs from a common effect for subsequent events. HR was estimated using a PWP model, with treatment, dialysis type and region as covariates.
  • Daprodustat vs Darbepoetin Alfa · Chi-squared · p = 0.8989 · Hazard ratio (hr): 1.16 · 95% CI 0.92 to 1.46Subsequent Event Hazard ratio is presented using Model 3. Model 3 assumed treatment effect for first event differs from a common effect for subsequent events. HR was estimated using a PWP model, with treatment, dialysis type and region as covariates.
SecondaryTime to First Occurrence of Adjudicated CV Mortality or Non-Fatal MI During CV Events Follow-up Time Period

Time to first occurrence of adjudicated CV mortality or non-fatal MI was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 4.3 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated CV Mortality or Non-Fatal MI During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatDarbepoetin Alfa
Time to First Occurrence of Adjudicated CV Mortality or Non-Fatal MI During CV Events Follow-up Time Period5.36 (4.62 to 6.18)4.98 (4.27 to 5.77)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Wald test · p = 0.7673 · Hazard ratio (hr): 1.08 · 95% CI 0.88 to 1.33Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, current ESA use at randomization, and region as covariates.
SecondaryTime to First Occurrence of All-Cause Hospitalization During CV Events Follow-up Time Period

All-cause hospitalization events were hospital admissions recorded on the hospitalization electronic case report form (eCRF) form with a hospitalization duration \>=24 hours. Time to first occurrence of all-cause hospitalization was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 4.3 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of All-Cause Hospitalization During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatDarbepoetin Alfa
Time to First Occurrence of All-Cause Hospitalization During CV Events Follow-up Time Period41.13 (38.59 to 43.80)38.99 (36.54 to 41.56)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Wald test · p = 0.8601 · Hazard ratio (hr): 1.05 · 95% CI 0.96 to 1.15Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, current ESA use at randomization, and region as covariates.
SecondaryTime to First Occurrence of All-Cause Hospital Re-admission Within 30 Days During CV Events Follow-up Time Period

All-cause hospital re-admissions within 30days are defined as hospital admissions recorded on hospitalization electronic case record form with hospitalization duration of \>=24 hours and admission date within 30days following previous discharge date of all-cause hospitalization event, where previous hospitalization was \>=24hours.Time to first occurrence of all-cause hospital re-admission within 30days was analyzed using Cox proportional hazards regression model with treatment group, current ESA use at randomization and region as covariates.Time to the first occurrence was computed as(event date - randomization date)+1. Incidence rate per 100 person years calculated as(100\*number of participants with at least 1event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event+cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 4.3 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of All-Cause Hospital Re-admission Within 30 Days During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatDarbepoetin Alfa
Time to First Occurrence of All-Cause Hospital Re-admission Within 30 Days During CV Events Follow-up Time Period7.78 (6.87 to 8.79)7.55 (6.65 to 8.55)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Wald test · p = 0.6207 · Hazard ratio (hr): 1.03 · 95% CI 0.86 to 1.22Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, current ESA use at randomization, and region as covariates.
SecondaryTime to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure or Thromboembolic Events During CV Events Follow-up Time Period

Time to first occurrence of adjudicated MACE or hospitalization for heart failure or thromboembolic events were analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 4.3 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure or Thromboembolic Events During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatDarbepoetin Alfa
Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure or Thromboembolic Events During CV Events Follow-up Time Period14.60 (13.33 to 15.96)13.32 (12.11 to 14.61)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Wald test · p = 0.9393 · Hazard ratio (hr): 1.11 · 95% CI 0.97 to 1.26Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, current ESA use at randomization, and region as covariates.
SecondaryTime to First Occurrence of Adjudicated Hospitalization for Heart Failure During CV Events Follow-up Time Period

Time to first occurrence of adjudicated hospitalization for heart failure was analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 4.3 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated Hospitalization for Heart Failure During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatDarbepoetin Alfa
Time to First Occurrence of Adjudicated Hospitalization for Heart Failure During CV Events Follow-up Time Period4.05 (3.41 to 4.78)3.30 (2.73 to 3.96)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Wald test · p = 0.9412 · Hazard ratio (hr): 1.22 · 95% CI 0.95 to 1.56Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, current ESA use at randomization, and region as covariates.
SecondaryTime to First Occurrence of Adjudicated Thromboembolic Events During CV Events Follow-up Time Period

Time to first occurrence of adjudicated thromboembolic events were analyzed using a Cox proportional hazards regression model with treatment group, current ESA use at randomization, and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) + 1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 4.3 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Adjudicated Thromboembolic Events During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatDarbepoetin Alfa
Time to First Occurrence of Adjudicated Thromboembolic Events During CV Events Follow-up Time Period1.81 (1.39 to 2.31)1.43 (1.07 to 1.89)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Wald test · p = 0.8994 · Hazard ratio (hr): 1.27 · 95% CI 0.88 to 1.84Hazard ratio was estimated using a Cox proportional hazard regression model with treatment group, current ESA use at randomization, and region as covariates.
SecondaryTime to First Occurrence of Confirmed 40% Decline in eGFR During CV Events Follow-up Time Period

Time to first occurrence of confirmed 40% decline in eGFR was analyzed using a Fine \& Gray's proportional subdistribution hazard regression model with treatment group, Baseline ESA use and region as covariates. Time to the first occurrence was computed as (event date minus randomization date)+1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 4.3 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Confirmed 40% Decline in eGFR During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatDarbepoetin Alfa
Time to First Occurrence of Confirmed 40% Decline in eGFR During CV Events Follow-up Time Period8.21 (7.04 to 9.52)8.90 (7.69 to 10.24)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Wald test · p = 0.2073 · Subdistribution hazard ratio: 0.92 · 95% CI 0.75 to 1.13Subdistribution hazard ratio was estimated using Fine \& Gray's proportional subdistribution hazard regression model with treatment group, Baseline ESA use, and region as covariates.
SecondaryTime to First Occurrence of Chronic Dialysis During CV Events Follow-up Time Period

Time to first occurrence of chronic dialysis was analyzed using a Fine \& Gray's proportional subdistribution hazard regression model with treatment group, Baseline ESA use and region as covariates. Chronic dialysis is defined by either initiating dialysis for \>=90 days or not initiating chronic dialysis when dialysis is indicated. Time to the first occurrence was computed as (event date minus randomization date)+1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 4.3 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Chronic Dialysis During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatDarbepoetin Alfa
Time to First Occurrence of Chronic Dialysis During CV Events Follow-up Time Period12.20 (10.74 to 13.81)12.06 (10.63 to 13.62)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Wald test · p = 0.5068 · Subdistribution hazard ratio: 1.00 · 95% CI 0.84 to 1.19Subdistribution hazard ratio was estimated using Fine \& Gray's proportional subdistribution hazard regression model with treatment group, Baseline ESA use, and region as covariates.
SecondaryTime to First Occurrence of Kidney Transplant During CV Events Follow-up Time Period

Time to first occurrence of kidney transplant were analyzed using a Fine \& Gray's proportional subdistribution hazard regression model with treatment group, Baseline ESA use and region as covariates. Time to the first occurrence was computed as (event date minus randomization date)+1. The incidence rate per 100 person years calculated as (100\*number of participants with at least 1 event)/first event person-years) is presented along with 95% CI. First event person years=(cumulative total time to first event for participants who have the event + cumulative total of censored time for participants without the event)/365.25, based on the CV follow-up time period.

Time frame:
Up to 4.3 person-years for CV follow-up time period
Reported as:
Number · Events per 100 person years
Time to First Occurrence of Kidney Transplant During CV Events Follow-up Time Period
Events per 100 person yearsDaprodustatDarbepoetin Alfa
Time to First Occurrence of Kidney Transplant During CV Events Follow-up Time Period1.00 (0.63 to 1.50)1.14 (0.75 to 1.66)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Wald test · p = 0.3285 · Subdistribution hazard ratio: 0.88 · 95% CI 0.51 to 1.54Subdistribution hazard ratio was estimated using Fine \& Gray's proportional subdistribution hazard regression model with treatment group, Baseline ESA use, and region as covariates.
SecondaryChange From Baseline in Post-randomization Hgb Levels at Week 52

Blood samples were collected from participants for Hgb measurements. Change from Baseline was defined as post-randomization value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using mixed model repeated measures (MMRM) model fitted from Baseline up to Week 52, excluding values collected during the stabilization period, with factors for treatment, time, current ESA use, region, Baseline Hgb and Baseline Hgb by time and treatment by time interactions.

Time frame:
Baseline (Pre-dose on Day 1) and Week 52
Reported as:
Least squares mean · Grams per deciliter
Change From Baseline in Post-randomization Hgb Levels at Week 52
Grams per deciliterDaprodustatDarbepoetin Alfa
Change From Baseline in Post-randomization Hgb Levels at Week 520.76 ± 0.0290.73 ± 0.029
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Ls mean difference: 0.03 · 95% CI -0.05 to 0.11
SecondaryNumber of Hgb Responders in the Hgb Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)

Mean Hgb during the evaluation period was defined as the mean of all evaluable Hgb values during the evaluation period (Week 28 to Week 52) including any evaluable unscheduled Hgb values that were taken during this time period. Hgb responders were defined as participants with a mean Hgb during the evaluation period that falls within the Hgb analysis range of 10-11.5 g/dL.

Time frame:
Week 28 to Week 52
Reported as:
Count of participants · Participants
Number of Hgb Responders in the Hgb Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)
ParticipantsDaprodustatDarbepoetin Alfa
Number of Hgb Responders in the Hgb Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)11671063
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in response rate: 8.3 · 95% CI 5.2 to 11.4Cochran-Mantel-Haenszel (CMH) test adjusted for current ESA use and region was used to compare the number of responders between the treatment groups.
SecondaryPercentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Non-inferiority Analysis

Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the evaluation period (Week 28 to Week 52), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during evaluation period is calculated as time in range during the evaluation period / \[Earlier of (Date of the last evaluable Hgb value, Week 52 visit date) - Later of (Date of the first evaluable Hgb value that between Week 16 and Week 52 inclusive, Week 28 visit date)\].

Time frame:
Week 28 to Week 52
Reported as:
Median · Percentage of days
Percentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Non-inferiority Analysis
Percentage of daysDaprodustatDarbepoetin Alfa
Percentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Non-inferiority Analysis70.5 (0.0 to 100.0)63.2 (0.0 to 100.0)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Mean difference (final values): 4.57 · 95% CI 2.04 to 7.11Hodges-Lehmann estimate of the treatment difference (daprodustat-darbepoetin alfa) and associated two-sided asymptotic 95% CI is presented.
SecondaryPercentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Superiority Analysis

Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the evaluation period (Week 28 to Week 52), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during evaluation period is calculated as time in range during the evaluation period / \[Earlier of (Date of the last evaluable Hgb value, Week 52 visit date) - Later of (Date of the first evaluable Hgb value that between Week 16 and Week 52 inclusive, Week 28 visit date)\].

Time frame:
Week 28 to Week 52
Reported as:
Median · Percentage of days
Percentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Superiority Analysis
Percentage of daysDaprodustatDarbepoetin Alfa
Percentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Superiority Analysis70.5 (0.0 to 100.0)63.2 (0.0 to 100.0)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · van Elteren test · p = <0.0001 · Probability: 0.55 · 95% CI 0.53 to 0.57Mann-Whitney estimate (Probability) of the treatment effect has been presented.
SecondaryPercentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Non-inferiority Analysis

Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the maintenance period (Week 28 to end of study), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during maintenance period is calculated as time in range during the maintenance period / \[Earlier of (Date of the last evaluable Hgb value, End of study date)- Later of (Date of the first evaluable Hgb value that is on or after week 16, Week 28 visit date)\].

Time frame:
Week 28 to end of study (4.3 person-years for follow-up time period)
Reported as:
Median · Percentage of days
Percentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Non-inferiority Analysis
Percentage of daysDaprodustatDarbepoetin Alfa
Percentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Non-inferiority Analysis66.1 (0.0 to 100.0)62.1 (0.0 to 100.0)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Median difference (final values): 3.94 · 95% CI 1.90 to 5.91Hodges-Lehmann estimate of the treatment difference (daprodustat-darbepoetin alfa) and associated two-sided asymptotic 95% CI is presented.
SecondaryPercentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Superiority Analysis

Percentage of days for which a participant's Hgb was within the analysis range of 10-11.5 g/dL (both inclusive) during the maintenance period (Week 28 to end of study), including any unscheduled evaluable Hgb values that were taken during this time period was calculated. Percentage of time in the analysis range during maintenance period is calculated as time in range during the maintenance period / \[Earlier of (Date of the last evaluable Hgb value, End of study date)- Later of (Date of the first evaluable Hgb value that is on or after week 16, Week 28 visit date)\].

Time frame:
Week 28 to end of study (4.3 person-years for follow-up time period)
Reported as:
Median · Percentage of days
Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Superiority Analysis
Percentage of daysDaprodustatDarbepoetin Alfa
Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Superiority Analysis66.1 (0.0 to 100.0)62.1 (0.0 to 100.0)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · van Elteren test · p = <0.0001 · Probability: 0.54 · 95% CI 0.52 to 0.56Mann-Whitney estimate (Probability) of the treatment effect has been presented.
SecondaryChange From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Blood Pressure (MAP) at Week 52

SBP, DBP and MAP were measured in a seated position after at least a 5-minutes of rest. MAP is the average (BP) in an individual's arteries during a single cardiac cycle. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using MMRM model with treatment group + time + current ESA use at randomization + region + Baseline value + Baseline value\*time + treatment group\*time, using an unstructured covariance matrix. Data for post-dialysis BP measurements have been presented.

Time frame:
Baseline (Week -4) and Week 52
Reported as:
Least squares mean · Millimeter of mercury
Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Blood Pressure (MAP) at Week 52
Millimeter of mercuryDaprodustatDarbepoetin Alfa
SBP, n=1913, 1884-0.62 ± 0.488-1.17 ± 0.479
DBP, n=1912, 18840.06 ± 0.267-0.59 ± 0.262
MAP, n=1912, 1884-0.17 ± 0.300-0.77 ± 0.294
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.7916 · Ls mean difference: 0.56 · 95% CI -0.79 to 1.90The difference in change from Baseline in SBP at Week 52 was analyzed with a MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9581 · Ls mean difference: 0.65 · 95% CI -0.09 to 1.38The difference in change from Baseline in DBP at Week 52 was analyzed with a MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9241 · Ls mean difference: 0.60 · 95% CI -0.22 to 1.43The difference in change from Baseline in MAP at Week 52 was analyzed with a MMRM approach with an unstructured covariance matrix to compare the difference in LS means between arms.
SecondaryChange From Baseline in SBP, DBP, MAP at End of Treatment

SBP, DBP and MAP were measured in a seated position after at least a 5-minutes of rest. MAP is an average BP in an individual's arteries during a single cardiac cycle. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date. Analysis was performed using ANCOVA model with terms for treatment group, current ESA use at randomization, region and Baseline value. Data for post-dialysis BP measurements have been presented.

Time frame:
Baseline (Week -4) and 51.1 months
Reported as:
Least squares mean · Millimeter of mercury
Change From Baseline in SBP, DBP, MAP at End of Treatment
Millimeter of mercuryDaprodustatDarbepoetin Alfa
SBP, n=1919, 1884-1.19 ± 0.395-1.10 ± 0.398
DBP, n=1918, 1884-0.26 ± 0.229-0.38 ± 0.231
MAP, n=1918, 1884-0.57 ± 0.248-0.62 ± 0.251
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · ANCOVA · p = 0.4420 · Ls mean difference: -0.08 · 95% CI -1.18 to 1.02For SBP: Treatment group comparisons were based on an ANCOVA model with terms for treatment group, current ESA use at randomization, region and Baseline value.
  • Daprodustat vs Darbepoetin Alfa · ANCOVA · p = 0.6369 · Ls mean difference: 0.11 · 95% CI -0.52 to 0.75For DBP: Treatment group comparisons were based on an ANCOVA model with terms for treatment group, current ESA use at randomization, region and Baseline value.
  • Daprodustat vs Darbepoetin Alfa · ANCOVA · p = 0.5490 · Ls mean difference: 0.04 · 95% CI -0.65 to 0.74For MAP: Treatment group comparisons were based on an ANCOVA model with terms for treatment group, current ESA use at randomization, region and Baseline value.
SecondaryBlood Pressure (BP) Exacerbation Event Rate Per 100 Participant Years

BP exacerbation event (based on post-dialysis) was defined as: SBP \>= 25 millimeter of mercury (mmHg) increased from Baseline or SBP \>=180 mmHg; DBP \>=15 mmHg increased from Baseline or DBP \>=110 mmHg. The BP exacerbation events per 100 participant years was estimated using the negative binomial model with treatment, current ESA use at randomization and region as covariates and the logarithm of time on-treatment as an offset variable. Data for post-dialysis BP measurements have been presented.

Time frame:
Day 1 to end of treatment (51.1 months)
Reported as:
Number · Events per 100 participant years
Blood Pressure (BP) Exacerbation Event Rate Per 100 Participant Years
Events per 100 participant yearsDaprodustatDarbepoetin Alfa
Blood Pressure (BP) Exacerbation Event Rate Per 100 Participant Years138.50 (128.58 to 149.18)157.35 (146.30 to 169.23)
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Negative binomial model · p = 0.0074 · Ratio of exacerbation rate: 0.88 · 95% CI 0.79 to 0.98Ratio of model estimated exacerbation rates and CIs estimated using negative binomial model with treatment,current ESA use at randomization and region as covariates and logarithm of time on treatment as offset variable for treatment group comparison.
SecondaryNumber of Participants With at Least One BP Exacerbation Event During Study

BP exacerbation was defined as: SBP \>= 25 mmHg increased from Baseline or SBP \>=180 mmHg; DBP \>=15 mmHg increased from Baseline or DBP \>=110 mmHg. Number of participants with at least one BP exacerbation event is presented.

Time frame:
Day 1 to end of treatment (51.1 months)
Reported as:
Count of participants · Participants
Number of Participants With at Least One BP Exacerbation Event During Study
ParticipantsDaprodustatDarbepoetin Alfa
Number of Participants With at Least One BP Exacerbation Event During Study9391012
SecondaryPercentage of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria

Percentage of participants permanently stopping randomized treatment due to meeting rescue criteria has been presented.

Time frame:
Day 1 to 51.1 months
Reported as:
Number · Percentage of participants
Percentage of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria
Percentage of participantsDaprodustatDarbepoetin Alfa
Percentage of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria2.03.3
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · Wald test · p = 0.0113 · Hazard ratio (hr): 0.63 · 95% CI 0.42 to 0.94Hazard ratio was estimated using a Cox proportional hazard regression model adjusted for treatment group, current ESA use and region.
SecondaryChange From Baseline in On-treatment Physical Component Score (PCS) Using Short Form (SF)-36 Health-related Quality of Life (HRQoL) Questionnaire at Weeks 8, 12, 28, 52

The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). The PCS is an average score derived from 4 domains (physical functioning, role-physical, bodily pain and general health) representing overall physical health. PCS ranges from 0 to 100; higher score represents better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in On-treatment Physical Component Score (PCS) Using Short Form (SF)-36 Health-related Quality of Life (HRQoL) Questionnaire at Weeks 8, 12, 28, 52
Scores on a scaleDaprodustatDarbepoetin Alfa
Week 8, n=1238,11870.42 ± 0.1690.78 ± 0.172
Week 12, n=1237,12270.60 ± 0.1710.71 ± 0.172
Week 28, n=968,9560.16 ± 0.1970.04 ± 0.198
Week 52, n=804,780-0.32 ± 0.218-0.12 ± 0.221
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9320 · Ls mean difference: -0.36 · 95% CI -0.83 to 0.11Week8:Model was fitted from Baseline up to Week52 and model adjusted Week8 data has been presented, with factors for treatment, time,current ESA use at randomization, region,Baseline value and Baseline value by time and treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.6761 · Ls mean difference: -0.11 · 95% CI -0.59 to 0.36Week12:Model was fitted from Baseline up to Week52 and model adjusted Week12 data has been presented,with factors for treatment, time,current ESA use at randomization, region, Baseline value and Baseline value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.3335 · Ls mean difference: 0.12 · 95% CI -0.43 to 0.67Week28:Model was fitted from Baseline up to Week52 and model adjusted Week28 data has been presented,with factors for treatment, time,current ESA use at randomization, region, Baseline value and Baseline value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.7423 · Ls mean difference: -0.20 · 95% CI -0.81 to 0.41Week52:Model was fitted from Baseline up to Week52 and model adjusted Week52 data has been presented,with factors for treatment, time,current ESA use at randomization, region, Baseline value and Baseline value by time \& treatment by time interactions
SecondaryChange From Baseline in On-treatment Mental Component Score (MCS) Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52

The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). MCS is an average score derived from 4 domains (vitality, social functioning, role-emotional and mental health) representing overall mental health. MCS ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in On-treatment Mental Component Score (MCS) Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52
Scores on a scaleDaprodustatDarbepoetin Alfa
Week 8, n=1238,11870.08 ± 0.2170.37 ± 0.221
Week 12, n=1237,12270.02 ± 0.2230.18 ± 0.224
Week 28, n=968,956-0.35 ± 0.244-0.02 ± 0.245
Week 52, n=804,780-0.71 ± 0.290-0.35 ± 0.294
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8268 · Ls mean difference: -0.29 · 95% CI -0.90 to 0.32Week8:Model was fitted from Baseline up to Week52 and model adjusted Week8 data has been presented,with factors for treatment, time,current ESA use at randomization, region, Baseline value and Baseline value by time \& treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.6851 · Ls mean difference: -0.15 · 95% CI -0.77 to 0.47Week12:Model was fitted from Baseline up to Week52 and model adjusted Week12 data has been presented,with factors for treatment, time,current ESA use at randomization, region, Baseline value and Baseline value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8316 · Ls mean difference: -0.33 · 95% CI -1.01 to 0.35Week28:Model was fitted from Baseline up to Week52 and model adjusted Week28 data has been presented,with factors for treatment, time,current ESA use at randomization, region, Baseline value and Baseline value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8032 · Ls mean difference: -0.35 · 95% CI -1.16 to 0.46Week52:Model was fitted from Baseline up to Week52 and model adjusted Week52 data has been presented,with factors for treatment, time,current ESA use at randomization, region, Baseline value and Baseline value by time \& treatment by time interactions
SecondaryChange From Baseline in On-treatment SF-36 HRQoL Scores for Bodily Pain, General Health, Mental Health, Role-Emotional, Role-Physical, Social Functioning at Weeks 8, 12, 28, 52

The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: bodily pain (b pain), general health (GH), mental health (MH), role-emotional (RE) (role limitations caused by emotional problems), role-physical (RP) (role limitations caused by physical problems), social functioning (SF), physical functioning and vitality. Each domain is scored from 0 (poorer health) to 100 (better health). Each domain score ranges from 0 to 100, higher score indicates a better health state and better functioning. Change from Baseline (BL) was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in On-treatment SF-36 HRQoL Scores for Bodily Pain, General Health, Mental Health, Role-Emotional, Role-Physical, Social Functioning at Weeks 8, 12, 28, 52
Scores on a scaleDaprodustatDarbepoetin Alfa
Bodily pain: Week 8, n=1238,11870.11 ± 0.2210.45 ± 0.225
Bodily pain: Week 12, n=1237,12270.35 ± 0.2230.50 ± 0.224
Bodily pain: Week 28, n=968,956-0.48 ± 0.2610.02 ± 0.263
Bodily pain: Week 52, n=804,780-0.34 ± 0.2830.13 ± 0.288
General health: Week 8, n=1238,11870.36 ± 0.1710.43 ± 0.174
General health: Week 12, n=1237,12270.28 ± 0.1740.48 ± 0.175
General health: Week 28, n=968,9560.14 ± 0.2000.04 ± 0.201
General health: Week 52, n=804,780-0.27 ± 0.220-0.19 ± 0.224
Mental health: Week 8, n=1238,1187-0.19 ± 0.2040.12 ± 0.208
Mental health: Week 12, n=1237,1227-0.07 ± 0.210-0.09 ± 0.211
Mental health: Week 28, n=968,956-0.67 ± 0.231-0.37 ± 0.232
Mental health: Week 52, n=804,780-0.85 ± 0.271-0.61 ± 0.275
Role-emotional: Week 8, n=1238,11870.45 ± 0.2530.54 ± 0.258
Role-emotional: Week 12, n=1237,12270.17 ± 0.2580.43 ± 0.259
Role-emotional: Week 28, n=968,956-0.30 ± 0.2900.07 ± 0.292
Role-emotional: Week 52, n=804,780-0.90 ± 0.339-0.38 ± 0.344
Role-physical: Week 8, n=1238,11870.33 ± 0.2020.83 ± 0.205
Role-physical: Week 12, n=1237,12270.40 ± 0.2030.73 ± 0.204
Role-physical: Week 28, n=968,9560.06 ± 0.2300.00 ± 0.232
Role-physical: Week 52, n=804,780-0.63 ± 0.259-0.44 ± 0.263
Social functioning: Week 8, n=1238,11870.19 ± 0.2240.82 ± 0.228
Social functioning: Week 12, n=1237,12270.21 ± 0.2240.53 ± 0.225
Social functioning: Week 28, n=968,9560.04 ± 0.2470.17 ± 0.249
Social functioning: Week 52, n=804,780-0.58 ± 0.282-0.20 ± 0.286
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8562 · Ls mean difference: -0.34 · 95% CI -0.95 to 0.28B pain,Week8:Model was fitted from Baseline up to Week52 and model adjusted Week8 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.6849 · Ls mean difference: -0.15 · 95% CI -0.77 to 0.47B pain,Week12:Model was fitted from Baseline up to Week52 and model adjusted Week12 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9074 · Ls mean difference: -0.49 · 95% CI -1.22 to 0.24B pain,Week28:Model was fitted from Baseline up to Week52 and model adjusted Week28 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8765 · Ls mean difference: -0.47 · 95% CI -1.26 to 0.32B pain,Week52:Model was fitted from Baseline up to Week52 and model adjusted Week52 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.6252 · Ls mean difference: -0.08 · 95% CI -0.56 to 0.40GH,Week8:Model was fitted from Baseline up to Week52 and model adjusted Week8 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.7852 · Ls mean difference: -0.20 · 95% CI -0.68 to 0.29GH,Week12:Model was fitted from Baseline up to Week52 and model adjusted Week12 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.3614 · Ls mean difference: 0.10 · 95% CI -0.46 to 0.66GH,Week28:Model was fitted from Baseline up to Week52 and model adjusted Week28 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.5991 · Ls mean difference: -0.08 · 95% CI -0.70 to 0.54GH,Week52:Model was fitted from Baseline up to Week52 and model adjusted Week52 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8526 · Ls mean difference: -0.31 · 95% CI -0.88 to 0.27MH,Week8:Model was fitted from Baseline up to Week52 and model adjusted Week8 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.4673 · Ls mean difference: 0.02 · 95% CI -0.56 to 0.61MH,Week12:Model was fitted from Baseline up to Week52 and model adjusted Week12 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8262 · Ls mean difference: -0.31 · 95% CI -0.95 to 0.33MH,Week28:Model was fitted from Baseline up to Week52 and model adjusted Week28 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.7380 · Ls mean difference: -0.25 · 95% CI -1.00 to 0.51MH,Week52:Model was fitted from Baseline up to Week52 and model adjusted Week52 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.5997 · Ls mean difference: -0.09 · 95% CI -0.80 to 0.62RE,Week8:Model was fitted from Baseline up to Week52 and model adjusted Week8 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.7649 · Ls mean difference: -0.26 · 95% CI -0.98 to 0.45RE,Week12:Model was fitted from Baseline up to Week52 and model adjusted Week12 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8175 · Ls mean difference: -0.37 · 95% CI -1.18 to 0.43RE,Week28:Model was fitted from Baseline up to Week52 and model adjusted Week28 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8591 · Ls mean difference: -0.52 · 95% CI -1.47 to 0.43RE,Week52:Model was fitted from Baseline up to Week52 and model adjusted Week52 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9588 · Ls mean difference: -0.50 · 95% CI -1.06 to 0.06RP,Week8:Model was fitted from Baseline up to Week52 and model adjusted Week8 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8761 · Ls mean difference: -0.33 · 95% CI -0.90 to 0.23RP,Week12:Model was fitted from Baseline up to Week52 and model adjusted Week12 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.4293 · Ls mean difference: 0.06 · 95% CI -0.58 to 0.70RP,Week28:Model was fitted from Baseline up to Week52 and model adjusted Week28 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.6983 · Ls mean difference: -0.19 · 95% CI -0.92 to 0.53RP,Week52:Model was fitted from Baseline up to Week52 and model adjusted Week52 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9743 · Ls mean difference: -0.62 · 95% CI -1.25 to 0.00SF,Week8:Model was fitted from Baseline up to Week52 and model adjusted Week8 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8405 · Ls mean difference: -0.32 · 95% CI -0.94 to 0.31SF,Week12:Model was fitted from Baseline up to Week52 and model adjusted Week12 data has been presented, with factors for treatment, time,current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.6459 · Ls mean difference: -0.13 · 95% CI -0.82 to 0.56SF,Week28:Model was fitted from Baseline up to Week52 and model adjusted Week28 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8272 · Ls mean difference: -0.38 · 95% CI -1.17 to 0.41SF,Week52:Model was fitted from Baseline up to Week52 and model adjusted Week52 data has been presented, with factors for treatment, time, current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions
SecondaryChange From Baseline in On-treatment Vitality Scores Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52

The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). Vitality score ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in On-treatment Vitality Scores Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52
Scores on a scaleDaprodustatDarbepoetin Alfa
Week 8, n=1238,11870.35 ± 0.1920.90 ± 0.195
Week 12, n=1237,12270.62 ± 0.2000.74 ± 0.201
Week 28, n=968,9560.22 ± 0.2220.32 ± 0.223
Week 52, n=804,780-0.14 ± 0.2500.35 ± 0.253
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9786 · Ls mean difference: -0.56 · 95% CI -1.09 to -0.02Week 8: Model was fitted from Baseline up to Week 52 and model adjusted Week 8 data has been presented,with factors for treatment, time,current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.6642 · Ls mean difference: -0.12 · 95% CI -0.68 to 0.44Week 12: Model was fitted from Baseline up to Week 52 and model adjusted Week 12 data has been presented,with factors for treatment, time,current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.6261 · Ls mean difference: -0.10 · 95% CI -0.72 to 0.52Week 28: Model was fitted from Baseline up to Week 52 and model adjusted Week 28 data has been presented,with factors for treatment, time,current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9161 · Ls mean difference: -0.49 · 95% CI -1.19 to 0.21Week 52: Model was fitted from Baseline up to Week 52 and model adjusted Week 52 data has been presented,with factors for treatment, time,current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions.
SecondaryChange From Baseline in On-treatment Physical Functioning Domain Scores Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52

The SF-36 acute version 2 is a 36-item generic quality of life instrument designed to measure a participant's level of performance in the following 8 health domains: physical functioning, role-physical (role limitations caused by physical problems), social functioning, bodily pain, mental health, role-emotional (role limitations caused by emotional problems), vitality and general health. Each domain is scored from 0 (poorer health) to 100 (better health). Physical functioning score ranges from 0 to 100; higher scores represent better health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in On-treatment Physical Functioning Domain Scores Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52
Scores on a scaleDaprodustatDarbepoetin Alfa
Week 8, n=1238,11870.51 ± 0.2000.83 ± 0.203
Week 12, n=1237,12270.65 ± 0.1950.52 ± 0.196
Week 28, n=968,9560.05 ± 0.224-0.10 ± 0.225
Week 52, n=804,780-0.69 ± 0.262-0.37 ± 0.266
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8703 · Ls mean difference: -0.32 · 95% CI -0.88 to 0.24Week 8: Model was fitted from Baseline up to Week 52 and model adjusted Week 8 data has been presented,with factors for treatment, time,current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.3167 · Ls mean difference: 0.13 · 95% CI -0.41 to 0.67Week 12: Model was fitted from Baseline up to Week 52 and model adjusted Week 12 data has been presented,with factors for treatment, time,current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.3155 · Ls mean difference: 0.15 · 95% CI -0.47 to 0.78Week 28: Model was fitted from Baseline up to Week 52 and model adjusted Week 28 data has been presented,with factors for treatment, time,current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8069 · Ls mean difference: -0.32 · 95% CI -1.06 to 0.41Week 52: Model was fitted from Baseline up to Week 52 and model adjusted Week 52 data has been presented,with factors for treatment, time,current ESA use at randomization, region, BL value and BL value by time \& treatment by time interactions.
SecondaryChange From Baseline in On-treatment Health Utility EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire Score at Week 52

EQ-5D-5L is self-assessment questionnaire, consisting of 5 items covering 5 dimensions (mobility, self care, usual activities, pain/discomfort and anxiety/depression). Each dimension is measured by 5-point Likert scale (1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems). Responses for 5 dimensions together formed a 5-figure description of health state (e.g.11111 indicates no problems in all 5 dimensions). Each of these 5 figure health states were converted to a single index score by applying country-specific value set formula that attaches weights to dimensions and levels. Range for EQ-5D-5L index score is -0.594 (worst health) to 1 (full health state). Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was latest non-missing pre-dose assessment on or before randomization date.

Time frame:
Baseline (Pre-dose on Day 1) and Week 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in On-treatment Health Utility EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire Score at Week 52
Scores on a scaleDaprodustatDarbepoetin Alfa
Change From Baseline in On-treatment Health Utility EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire Score at Week 52-0.0253 ± 0.00842-0.0018 ± 0.00883
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9724 · Ls mean difference: -0.0234 · 95% CI -0.0474 to 0.0005MMRM model was fitted from Baseline up to Week 52 with factors for treatment, time, current ESA use, region, Baseline value and Baseline value by time and treatment by time interactions.
SecondaryChange From Baseline in On-treatment EQ Visual Analogue Scale (EQ-VAS) at Week 52

The EQ VAS records the respondent's self-rated health on a vertical VAS, ranging from 0 to 100, where 0 represents the worst imaginable health and 100 represents the best imaginable health. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Pre-dose on Day 1) and Week 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in On-treatment EQ Visual Analogue Scale (EQ-VAS) at Week 52
Scores on a scaleDaprodustatDarbepoetin Alfa
Change From Baseline in On-treatment EQ Visual Analogue Scale (EQ-VAS) at Week 52-0.7 ± 0.78-1.4 ± 0.82
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.2687 · Ls mean difference: 0.7 · 95% CI -1.5 to 2.9MMRM model was fitted from Baseline up to Week 52 with factors for treatment, time, current ESA use, region, Baseline value and Baseline value by time and treatment by time interactions.
SecondaryChange From Baseline in On-treatment Chronic Kidney Disease- Anemia Symptoms Questionnaire (CKD-AQ) at Weeks 8, 12, 28, 52

CKD-AQ is 21-item patient reported outcome measure assessing symptoms and symptom impact in participants with anemia associated with CKD. It had 3 domains: 1.Tired/Low Energy (LE)/Weak scale consisting of 10 items; 2.Chest Pain (CP)/Shortness of Breath (SOB) scale consisting of 4 items; and 3.Cognitive (Cog) scale consisting of 3 items. The 4 CKD-AQ single items are: shortness of breath, no activity; severity-short breath (S-SB), resting; difficulty standing (diff. std.)for long time (LT) and difficulty sleeping (diff sleep). Single-item were recorded based on a 0-100 scoring with 0=worst possible and 100=best possible score. Three domains scores were calculated as average of items in each domain and ranged from 0-100 where 0=worst possible and 100=best possible score. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Day 1) and Weeks 8, 12, 28, 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in On-treatment Chronic Kidney Disease- Anemia Symptoms Questionnaire (CKD-AQ) at Weeks 8, 12, 28, 52
Scores on a scaleDaprodustatDarbepoetin Alfa
Tired/Low energy/Weak domain: Week 8,n=1340,12941.72 ± 0.4242.94 ± 0.429
Tired/Low energy/Weak domain: Week 12,n=1341,13602.11 ± 0.4373.08 ± 0.434
Tired/Low energy/Weak domain: Week 28,n=1053,10471.27 ± 0.4951.87 ± 0.496
Tired/Low energy/Weak domain: Week 52,n=870,8650.20 ± 0.5541.77 ± 0.556
Chest pain/SOB domain: Week 8,n=1340,12940.63 ± 0.3581.83 ± 0.363
Chest pain/ SOB domain: Week 12,n=1341,13600.88 ± 0.3701.53 ± 0.368
Chest pain/ SOB domain: Week 28,n=1053,10470.01 ± 0.4240.53 ± 0.425
Chest pain/ SOB domain: Week 52,n=870,865-0.71 ± 0.4710.47 ± 0.473
Cognitive domain: Week 8,n=1340,12940.13 ± 0.4130.89 ± 0.419
Cognitive domain: Week 12,n=1341,1360-0.17 ± 0.4141.01 ± 0.412
Cognitive domain: Week 28,n=1053,1047-0.40 ± 0.4680.37 ± 0.469
Cognitive domain: Week 52,n=870,865-2.00 ± 0.526-0.35 ± 0.527
SOB, no activity: Week 8,n=1340,1294-0.1 ± 0.421.0 ± 0.42
SOB, no activity: Week 12,n=1341,13600.1 ± 0.430.4 ± 0.42
SOB, no activity: Week 28,n=1053,1047-1.1 ± 0.50-0.2 ± 0.50
SOB, no activity: Week 52,n=870,865-1.7 ± 0.57-1.6 ± 0.57
Severity-short breath, Resting: Week 8,n=1340,1294-0.3 ± 0.400.8 ± 0.40
Severity-short breath, Resting:Week 12,n=1341,1360-0.3 ± 0.420.0 ± 0.42
Severity-short breath, Resting:Week 28,n=1053,1047-1.1 ± 0.48-0.7 ± 0.48
Severity-short breath, Resting:Week 52,n=870,865-2.0 ± 0.53-0.5 ± 0.53
Diff std for long time: Week 8,n=1340,12941.0 ± 0.622.5 ± 0.63
Diff std for long time: Week 12,n=1341,13600.7 ± 0.631.6 ± 0.62
Diff std for long time: Week 28,n=1053,10470.4 ± 0.711.7 ± 0.71
Diff std for long time: Week 52,n=870,865-2.1 ± 0.761.2 ± 0.76
Difficulty sleeping: Week 8,n=1340,12941.6 ± 0.601.1 ± 0.61
Difficulty sleeping: Week 12,n=1341,13600.5 ± 0.602.0 ± 0.59
Difficulty sleeping: Week 28,n=1053,1047-0.7 ± 0.69-0.3 ± 0.70
Difficulty sleeping: Week 52,n=870,865-2.6 ± 0.78-0.3 ± 0.78
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9780 · Ls mean difference: -1.22 · 95% CI -2.40 to -0.03Tired/LE/Weak domain,Week8:Model was fitted from Baseline up to Week52 and model adjusted Week8 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9430 · Ls mean difference: -0.97 · 95% CI -2.18 to 0.23Tired/LE/Weak domain,Week12:Model was fitted from Baseline up to Week52 and model adjusted Week12 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8042 · Ls mean difference: -0.60 · 95% CI -1.98 to 0.77Tired/LE/Weak domain,Week28:Model was fitted from Baseline up to Week52 and model adjusted Week28 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9770 · Ls mean difference: -1.57 · 95% CI -3.11 to -0.03Tired/LE/Weak domain,Week52:Model was fitted from Baseline up to Week52 and model adjusted Week52 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9905 · Ls mean difference: -1.20 · 95% CI -2.20 to -0.20CP/SOB,Week8:Model was fitted from Baseline up to Week52 and model adjusted Week8 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · LS mean difference · p = 0.8939 · Ls mean difference: -0.65 · 95% CI -1.67 to 0.37CP/SOB,Week12:Model was fitted from Baseline up to Week52 and model adjusted Week12 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8070 · Ls mean difference: -0.52 · 95% CI -1.70 to 0.66CP/SOB,Week28:Model was fitted from Baseline up to Week52 and model adjusted Week28 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9615 · Ls mean difference: -1.18 · 95% CI -2.49 to 0.13CP/SOB,Week52:Model was fitted from Baseline up to Week52 and model adjusted Week52 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9015 · Ls mean difference: -0.76 · 95% CI -1.91 to 0.39Cog domain,Week8:Model was fitted from Baseline up to Week52 and model adjusted Week8 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9781 · Ls mean difference: -1.18 · 95% CI -2.32 to -0.03Cog domain,Week12:Model was fitted from Baseline up to Week52 and model adjusted Week12 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8778 · Ls mean difference: -0.77 · 95% CI -2.07 to 0.53Cog domain,Week28:Model was fitted from Baseline up to Week52 and model adjusted Week28 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9864 · Ls mean difference: -1.65 · 95% CI -3.11 to -0.19Cog domain,Week52:Model was fitted from Baseline up to Week52 and model adjusted Week52 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9725 · Ls mean difference: -1.1 · 95% CI -2.3 to 0.0SOB, no activity,Week8:Model was fitted from Baseline up to Week52 and model adjusted Week8 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.7188 · Ls mean difference: -0.3 · 95% CI -1.5 to 0.8SOB, no activity,Week12:Model was fitted from Baseline up to Week52 and model adjusted Week12 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8903 · Ls mean difference: -0.9 · 95% CI -2.3 to 0.5SOB, no activity,Week28:Model was fitted from Baseline up to Week52 and model adjusted Week28 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.5011 · Ls mean difference: 0.0 · 95% CI -1.6 to 1.6SOB, no activity,Week52:Model was fitted from Baseline up to Week52 and model adjusted Week52 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9716 · Ls mean difference: -1.1 · 95% CI -2.2 to 0.0S-SB,Resting, Week8:Model was fitted from Baseline up to Week52 and model adjusted Week8 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.6908 · Ls mean difference: -0.3 · 95% CI -1.4 to 0.9S-SB,Resting, Week12:Model was fitted from Baseline up to Week52 and model adjusted Week12 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.7462 · Ls mean difference: -0.5 · 95% CI -1.8 to 0.9S-SB,Resting, Week28:Model was fitted from Baseline up to Week52 and model adjusted Week28 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9770 · Ls mean difference: -1.5 · 95% CI -2.9 to 0.0S-SB,Resting, Week52:Model was fitted from Baseline up to Week52 and model adjusted Week52 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9471 · Ls mean difference: -1.4 · 95% CI -3.2 to 0.3Diff std for LT, Week8:Model was fitted from Baseline up to Week52 and model adjusted Week8 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8330 · Ls mean difference: -0.9 · 95% CI -2.6 to 0.9Diff std for LT, Week12:Model was fitted from Baseline up to Week52 and model adjusted Week12 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8918 · Ls mean difference: -1.2 · 95% CI -3.2 to 0.7Diff std for LT, Week28:Model was fitted from Baseline up to Week52 and model adjusted Week28 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9986 · Ls mean difference: -3.2 · 95% CI -5.4 to -1.1Diff std for LT, Week52:Model was fitted from Baseline up to Week52 and model adjusted Week52 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.3035 · Ls mean difference: 0.4 · 95% CI -1.2 to 2.1Diff sleep, Week8:Model was fitted from Baseline up to Week52 and model adjusted Week8 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9563 · Ls mean difference: -1.4 · 95% CI -3.1 to 0.2Diff sleep, Week12:Model was fitted from Baseline up to Week52 and model adjusted Week12 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.6548 · Ls mean difference: -0.4 · 95% CI -2.3 to 1.5Diff sleep, Week28:Model was fitted from Baseline up to Week52 and model adjusted Week28 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9832 · Ls mean difference: -2.4 · 95% CI -4.5 to -0.2Diff sleep, Week52:Model was fitted from Baseline up to Week52 and model adjusted Week52 data has been presented, with factors for treatment, time, current ESA use, region, BL value and BL value by time and treatment by time interactions.
SecondaryChange From Baseline in On-treatment Patient Global Impression of Severity (PGI-S) at Weeks 8, 12, 28, 52

The PGI-S is a 1-item questionnaire designed to assess participant's impression of disease severity on a 5-point disease severity scale (0=absent, 1=mild, 2=moderate, 3=severe, or 4=very severe). A higher score indicated more disease severity. Change from Baseline was calculated as on-treatment visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in On-treatment Patient Global Impression of Severity (PGI-S) at Weeks 8, 12, 28, 52
Scores on a scaleDaprodustatDarbepoetin Alfa
Week 8, n=1341,12950.00 ± 0.022-0.02 ± 0.022
Week 12, n=1341,13620.03 ± 0.022-0.02 ± 0.022
Week 28, n=1054,10510.05 ± 0.0250.09 ± 0.025
Week 52, n=871,8650.11 ± 0.0280.06 ± 0.029
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.6917 · Ls mean difference: 0.02 · 95% CI -0.05 to 0.08Week 8: Model was fitted from Baseline up to Week52 and model adjusted Week 8 data has been presented, with factors for treatment, time, current ESA use, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.9510 · Ls mean difference: 0.05 · 95% CI -0.01 to 0.11Week 12: Model was fitted from Baseline up to Week52 and model adjusted Week 12 data has been presented, with factors for treatment, time, current ESA use, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.1136 · Ls mean difference: -0.04 · 95% CI -0.11 to 0.03Week 28: Model was fitted from Baseline up to Week52 and model adjusted Week 28 data has been presented, with factors for treatment, time, current ESA use, region, Baseline value and Baseline value by time and treatment by time interactions.
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.8859 · Ls mean difference: 0.05 · 95% CI -0.03 to 0.13Week 52: Model was fitted from Baseline up to Week52 and model adjusted Week 52 data has been presented, with factors for treatment, time, current ESA use, region, Baseline value and Baseline value by time and treatment by time interactions.
SecondaryChange From Baseline in Post-randomization Estimated Glomerular Filtration Rate (eGFR) at Week 52

Blood samples were collected to analyze estimated glomerular filtration rate. Change from Baseline was calculated as post-Baseline visit value minus Baseline value. Baseline was defined as the latest non-missing pre-dose assessment on or before the randomization date.

Time frame:
Baseline (Pre-dose on Day 1) and Week 52
Reported as:
Least squares mean · mL per minute per 1.73 square meter
Change From Baseline in Post-randomization Estimated Glomerular Filtration Rate (eGFR) at Week 52
mL per minute per 1.73 square meterDaprodustatDarbepoetin Alfa
Change From Baseline in Post-randomization Estimated Glomerular Filtration Rate (eGFR) at Week 52-2.88 ± 0.193-2.67 ± 0.193
Statistical analysis
  • Daprodustat vs Darbepoetin Alfa · MMRM · p = 0.7716 · Ls mean difference: -0.20 · 95% CI -0.74 to 0.33MMRM model was fitted from Baseline up to Week 52 with factors for treatment, time, current ESA use at randomization, region, Baseline value and Baseline value by time and treatment by time interactions.

Adverse events

Collected over All-cause mortality, serious adverse events (SAEs) and non-SAEs were collected from Week -4 up to randomization (Day 1) during Run-in placebo period. All-cause mortality, treatment emergent serious adverse events (TESAEs) and non-serious treatment emergent adverse events (non-STEAEs) were collected from randomization (Day 1) up to 4.3 person-years for CV follow-up time period (Treatment Period). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Run-in Period: Placebo0/3,872 (0%)63/3,872 (1.6%)0/3,872 (0%)
Daprodustat301/1,937 (15.5%)850/1,937 (43.9%)851/1,937 (43.9%)
Darbepoetin Alfa298/1,935 (15.4%)703/1,933 (36.4%)825/1,933 (42.7%)
Most frequent serious events
Showing 10 of 760
Most frequent serious events
EventRun-in Period: PlaceboDaprodustatDarbepoetin Alfa
Chronic kidney diseaseRenal and urinary disorders1/387286/193749/1933
PneumoniaInfections and infestations3/387278/193775/1933
Acute kidney injuryRenal and urinary disorders1/387270/193747/1933
AzotaemiaRenal and urinary disorders1/387254/193735/1933
End stage renal diseaseRenal and urinary disorders0/387248/193736/1933
COVID-19Infections and infestations1/387239/193733/1933
Acute myocardial infarctionCardiac disorders1/387237/193726/1933
Urinary tract infectionInfections and infestations2/387233/193736/1933
AnaemiaBlood and lymphatic system disorders3/387233/193731/1933
Cardiac failure congestiveCardiac disorders1/387229/193720/1933
Most frequent other events
Most frequent other events
EventRun-in Period: PlaceboDaprodustatDarbepoetin Alfa
HypertensionVascular disorders0/3872247/1937264/1933
Oedema peripheralGeneral disorders0/3872198/1937162/1933
Urinary tract infectionInfections and infestations0/3872164/1937153/1933
DiarrhoeaGastrointestinal disorders0/3872149/1937139/1933
NasopharyngitisInfections and infestations0/3872118/1937133/1933
HyperkalaemiaMetabolism and nutrition disorders0/3872128/1937122/1933
ConstipationGastrointestinal disorders0/3872127/193788/1933
Back painMusculoskeletal and connective tissue disorders0/387282/1937105/1933
FallInjury, poisoning and procedural complications0/3872104/193788/1933
NauseaGastrointestinal disorders0/3872103/193784/1933

Baseline characteristics

All Randomized (Intent-to-treat \[ITT\]) Population comprised of all randomized participants. Participants were analyzed according to the treatment to which they were randomized.

Age, Continuous
Age, Continuous(Years)DaprodustatDarbepoetin AlfaTotal
Mean64.8 ± 14.0364.9 ± 13.8364.8 ± 13.93
Sex: Female, Male
Sex: Female, Male(Participants)DaprodustatDarbepoetin AlfaTotal
Female110210712173
Male8358641699
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DaprodustatDarbepoetin AlfaTotal
American Indian or Alaskan Native88100188
Asian - Central/South Asian Heritage5871129
Asian - East Asian Heritage245232477
Asian - Japanese Heritage538
Asian - South East Asian Heritage216229445
Black or African American183185368
Native Hawaiian or Other Pacific Islander7714
White - Arabic/North African Heritage191837
White - White/Caucasian/European Heritage107910372116
Mixed Asian Race123
Mixed Race365187
08

Study locations

578 sites
  • GSK Investigational Site
    Andalusia, Alabama 36420, United States
  • GSK Investigational Site
    Birmingham, Alabama 35249, United States
  • GSK Investigational Site
    Huntsville, Alabama 35805, United States
  • GSK Investigational Site
    Glendale, Arizona 85305, United States
  • GSK Investigational Site
    Mesa, Arizona 85202, United States
  • GSK Investigational Site
    Phoenix, Arizona 85016, United States
  • GSK Investigational Site
    Phoenix, Arizona 85027, United States
  • GSK Investigational Site
    Scottsdale, Arizona 48201, United States
  • GSK Investigational Site
    Tucson, Arizona 85745, United States
  • GSK Investigational Site
    Azusa, California 91702, United States
  • GSK Investigational Site
    Bakersfield, California 93308, United States
  • GSK Investigational Site
    Bakersfield, California 93309, United States
  • GSK Investigational Site
    Chula Vista, California 91910, United States
  • GSK Investigational Site
    Cudahy, California 90201, United States
  • GSK Investigational Site
    El Centro, California 92243, United States
  • GSK Investigational Site
    Escondido, California 92025, United States
  • GSK Investigational Site
    Glendale, California 91204, United States
  • GSK Investigational Site
    Granada Hills, California 91344, United States
  • GSK Investigational Site
    La Mesa, California 91942, United States
  • GSK Investigational Site
    La Palma, California 90623, United States
  • GSK Investigational Site
    Long Beach, California 90806, United States
  • GSK Investigational Site
    Los Angeles, California 90022, United States
  • GSK Investigational Site
    Los Angeles, California 90095, United States
  • GSK Investigational Site
    Montebello, California 90640, United States
  • GSK Investigational Site
    National City, California 91950, United States
  • GSK Investigational Site
    Riverside, California 92505, United States
  • GSK Investigational Site
    San Diego, California 92103, United States
  • GSK Investigational Site
    San Diego, California 92111, United States
  • GSK Investigational Site
    San Luis Obispo, California 93405, United States
  • GSK Investigational Site
    Simi Valley, California 93065, United States
  • GSK Investigational Site
    Tarzana, California 91356, United States
  • GSK Investigational Site
    Whittier, California 90602, United States
  • GSK Investigational Site
    Middlebury, Connecticut 06762, United States
  • GSK Investigational Site
    Washington, District of Columbia 20037, United States
  • GSK Investigational Site
    Aventura, Florida 33180, United States
  • GSK Investigational Site
    Boca Raton, Florida 33431, United States
  • GSK Investigational Site
    Coral Gables, Florida 33134, United States
  • GSK Investigational Site
    Cutler Bay, Florida 33189, United States
  • GSK Investigational Site
    Doral, Florida 33122, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33308, United States
  • GSK Investigational Site
    Homestead, Florida 33033, United States
  • GSK Investigational Site
    Hudson, Florida 34667, United States
  • GSK Investigational Site
    Jacksonville, Florida 32224, United States
  • GSK Investigational Site
    Jacksonville, Florida 32256, United States
  • GSK Investigational Site
    Lauderdale Lakes, Florida 33313, United States
  • GSK Investigational Site
    Miami Gardens, Florida 33169, United States
  • GSK Investigational Site
    Miami Lakes, Florida 33014, United States
  • GSK Investigational Site
    Miami, Florida 33126, United States
  • GSK Investigational Site
    Miami, Florida 33143, United States
  • GSK Investigational Site
    Miami, Florida 33145, United States
  • GSK Investigational Site
    Miami, Florida 33147, United States
  • GSK Investigational Site
    Miami, Florida 33150, United States
  • GSK Investigational Site
    Miami, Florida 33155, United States
  • GSK Investigational Site
    Miami, Florida 33156, United States
  • GSK Investigational Site
    Miami, Florida 33165, United States
  • GSK Investigational Site
    Miami, Florida 33169, United States
  • GSK Investigational Site
    Miami, Florida 33173, United States
  • GSK Investigational Site
    Ocala, Florida 34471, United States
  • GSK Investigational Site
    Orlando, Florida 32810, United States
  • GSK Investigational Site
    Pembroke Pines, Florida 33028, United States
  • GSK Investigational Site
    Port Charlotte, Florida 33952, United States
  • GSK Investigational Site
    South Miami, Florida 33143, United States
  • GSK Investigational Site
    Tampa, Florida 33612, United States
  • GSK Investigational Site
    Temple Terrace, Florida 33637, United States
  • GSK Investigational Site
    Atlanta, Georgia 30342, United States
  • GSK Investigational Site
    Augusta, Georgia 30904, United States
  • GSK Investigational Site
    Augusta, Georgia 30909, United States
  • GSK Investigational Site
    Augusta, Georgia 30912, United States
  • GSK Investigational Site
    Columbus, Georgia 31904, United States
  • GSK Investigational Site
    Nampa, Idaho 83687, United States
  • GSK Investigational Site
    Chicago, Illinois 60611, United States
  • GSK Investigational Site
    Chicago, Illinois 60643, United States
  • GSK Investigational Site
    Crystal Lake, Illinois 60014, United States
  • GSK Investigational Site
    Mount Prospect, Illinois 60056, United States
  • GSK Investigational Site
    Quincy, Illinois 62301, United States
  • GSK Investigational Site
    Springfield, Illinois 62702, United States
  • GSK Investigational Site
    Fort Wayne, Indiana 46845, United States
  • GSK Investigational Site
    Jeffersonville, Indiana 47130, United States
  • GSK Investigational Site
    Michigan City, Indiana 46360, United States
  • GSK Investigational Site
    Des Moines, Iowa 50309, United States
  • GSK Investigational Site
    Iowa City, Iowa 52242, United States
  • GSK Investigational Site
    Hutchinson, Kansas 67502, United States
  • GSK Investigational Site
    Wichita, Kansas 67214, United States
  • GSK Investigational Site
    Louisville, Kentucky 40202, United States
  • GSK Investigational Site
    Baton Rouge, Louisiana 70808, United States
  • GSK Investigational Site
    Baton Rouge, Louisiana 70836, United States
  • GSK Investigational Site
    Metairie, Louisiana 70006, United States
  • GSK Investigational Site
    Baltimore, Maryland 21287, United States
  • GSK Investigational Site
    Potomac, Maryland 20854, United States
  • GSK Investigational Site
    Takoma Park, Maryland 20912-6385, United States
  • GSK Investigational Site
    Boston, Massachusetts 02114, United States
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
  • GSK Investigational Site
    Kalamazoo, Michigan 49007, United States
  • GSK Investigational Site
    Pontiac, Michigan 48341, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55414, United States
  • GSK Investigational Site
    Jackson, Mississippi 39216, United States
  • GSK Investigational Site
    Tupelo, Mississippi 38801, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63106, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63110, United States
  • GSK Investigational Site
    North Platte, Nebraska 69101, United States

Showing the first 100 of 578 sites across 39 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ajay K. Singh, Kevin Carroll, John J. V. McMurray, Scott Solomon, Vivekanand Jha, Kirsten L. Johansen, Renato D. Lopes, Iain C. Macdougall, Gregorio T. Obrador, Sushrut S. Waikar, Christoph Wanner, David C. Wheeler, Andrzej Wiecek, Allison Blackorby, Borut Cizman, Alexander R. Cobitz, Rich Davies, Tara L. DiMino, Lata Kler, Amy M. Meadowcroft, Lin Taft, Vlado Perkovic for the ASCEND-ND Study Group. DAPRODUSTAT FOR THE TREATMENT OF ANEMIA IN PATIENTS NOT UNDERGOING DIALYSIS. N Engl J Med. 2021; DOI: 10.1056/NEJMoa2113380 PMID: 34739196
  • Perkovic V, Blackorby A, Cizman B, Carroll K, Cobitz AR, Davies R, DiMino TL, Jha V, Johansen KL, Lopes RD, Kler L, Macdougall IC, McMurray JJV, Meadowcroft AM, Obrador GT, Solomon S, Taft L, Wanner C, Waikar SS, Wheeler DC, Wiecek A, Singh AK. The ASCEND-ND trial: study design and participant characteristics. Nephrol Dial Transplant. 2022 Oct 19;37(11):2157-2170. doi: 10.1093/ndt/gfab318. PubMed 34865143 ↗
  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
  • Singh AK, Carroll K, McMurray JJV, Solomon S, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Wiecek A, Blackorby A, Cizman B, Cobitz AR, Davies R, DiMino TL, Kler L, Meadowcroft AM, Taft L, Perkovic V; ASCEND-ND Study Group. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med. 2021 Dec 16;385(25):2313-2324. doi: 10.1056/NEJMoa2113380. Epub 2021 Nov 5. PubMed 34739196 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Apr 2021, 54 months.

Results were first posted in Apr 2022, 11 months after primary completion.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 54 months is above that.

Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2016
First posted
Aug 24, 2016
StartActual
Sep 27, 2016
Primary completionActual
Apr 19, 2021
CompletionActual
Apr 19, 2021
Results first posted
Apr 14, 2022
Last update
Apr 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02876835
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 24, 2016
Start date
Sep 27, 2016
Primary completion
Apr 19, 2021
Completion
Apr 19, 2021
Results posted
Apr 14, 2022
Last update
Apr 2, 2024

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1278863

Start the discussion